All but one of these pandemic-proof mega-blockbusters achieved growth in what has been a remarkable year, where COVID-19 has ravaged the world. And Humira (adalimumab) retains its throne as the top-selling drug for the ninth year in a row, showcasing incredible staying power at the tail end of its product lifecycle.
Top 10 Best-Selling Drugs Of 2020
Listen to this article
One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed. AbbVie’s Humira easily retained its lead in 2020 with $20.3bn in sales. Gilead Sciences’ HIV triple combo Biktarvy was the fastest climber, entering the top 10 in eighth place after 53.2% growth in a year, while Avastin, Enbrel and Rituxan fell out of the list.
Candid conversations with C-suite leaders.
More from Growth
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
• By
A positive mindset can boost exercise motivation. Learn how mental shifts help you start—and stick with—a healthier fitness routine.
More from In Vivo
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.